Frank McCaughan

Dr. Frank McCaughan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
LSL Succony
L Succony
DRDm Rassl
Dm Rassl
ABAP Barker
AP Barker
FMFrank McCaughan
Frank McCaughan
RRRc Rintoul
Rc Rintoul

2 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
NHNamshik Han
Namshik Han
WHWoochang Hwang
Woochang Hwang
KTKonstantinos Tzelepis
Konstantinos Tzelepis
PSPatrick Schmerer
Patrick Schmerer
EYEliza Yankova
Eliza Yankova
TKTony Kouzarides
Tony Kouzarides
Data-driven computational analysis and simulation identified drug repurposing opportunities for COVID-19.

1 December 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
LPLinsey Porter
Linsey Porter
FMFrank McCaughan
Frank McCaughan

25 April 2024 in Respiratory Research
Verified
Journal Article
Open access
PDF file
MVMarta Vilà-González
Marta Vilà-González
LPLaetitia Pinte
Laetitia Pinte
RFRicardo Fradique
Ricardo Fradique
ECErika Causa
Erika Causa
HKHeleen Kool
Heleen Kool
LVLudovic Vallier
Ludovic Vallier
Background: Pulmonary ionocytes have been identified in the airway epithelium as a small population of ion transporting cells expressing high levels of CFTR (cystic fibrosis transmembrane conductance regulator), the gene mutated in cystic fibrosis. By providing an infinite source of airway epithelial cells (AECs), the use of human induced pluripotent stem cells (hiPSCs) could overcome some challenges of studying ionocytes. However, the production of AEC epithelia containing ionocytes from hiPSCs has proven difficult. Here, we present a platform to produce hiPSC-derived AECs (hiPSC-AECs) including ionocytes and investigate their role in the airway epithelium. Methods: hiPSCs were differentiated into lung progenitors, which were expanded as 3D organoids and matured by air-liquid interface culture as polarised hiPSC-AEC epithelia. Using CRISPR/Cas9 technology, we generated a hiPSCs knockout (KO) for FOXI1, a transcription factor that is essential for ionocyte specification. Differences between FOXI1 KO hiPSC-AECs and their wild-type (WT) isogenic controls were investigated by assessing gene and protein expression, epithelial composition, cilia coverage and motility, pH and transepithelial barrier properties. Results: Mature hiPSC-AEC epithelia contained basal cells, secretory cells, ciliated cells with motile cilia, pulmonary neuroendocrine cells (PNECs) and ionocytes. There was no difference between FOXI1 WT and KO hiPSCs in terms of their capacity to differentiate into airway progenitors. However, FOXI1 KO led to mature hiPSC-AEC epithelia without ionocytes with reduced capacity to produce ciliated cells. Conclusion: Our results suggest that ionocytes could have role beyond transepithelial ion transport by regulating epithelial properties and homeostasis in the airway epithelium.

2 February 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
WGWenrui Guo
Wenrui Guo
LPLinsey M Porter
Linsey M Porter
TCThomas Wm Crozier
Thomas Wm Crozier
MCMatthew Coates
Matthew Coates
AJAkhilesh Jha
Akhilesh Jha
FMFrank McCaughan
Frank McCaughan
Background: There are limited effective prophylactic/early treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral entry requires spike protein binding to the angiotensin-converting enzyme-2 receptor and cleavage by transmembrane serine protease 2 (TMPRSS2), a cell surface serine protease. Targeting of TMPRSS2 by either androgen blockade or direct inhibition is in clinical trials in early SARS-CoV-2 infection. Methods: We used differentiated primary human airway epithelial cells at the air–liquid interface to test the impact of targeting TMPRSS2 on the prevention of SARS-CoV-2 infection. Results: We first modelled the systemic delivery of compounds. Enzalutamide, an oral androgen receptor antagonist, had no impact on SARS-CoV-2 infection. By contrast, camostat mesylate, an orally available serine protease inhibitor, blocked SARS-CoV-2 entry. However, oral camostat is rapidly metabolised in the circulation, with poor airway bioavailability. We therefore modelled local airway administration by applying camostat to the apical surface of differentiated airway cultures. We demonstrated that a brief exposure to topical camostat effectively restricts SARS-CoV-2 infection. Conclusion: These experiments demonstrate a potential therapeutic role for topical camostat for pre- or post-exposure prophylaxis of SARS-CoV-2, which can now be evaluated in a clinical trial.

15 August 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MNMegan Neary
Megan Neary
JSJoanne Sharp
Joanne Sharp
EGEduardo Gallardo-Toledo
Eduardo Gallardo-Toledo
JHJoanne Herriott
Joanne Herriott
EKEdyta Kijak
Edyta Kijak
AOAndrew Owen
Andrew Owen
The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models. Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. This study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters. SARS-CoV-2 RNA was detectable in the throat swabs of the water-treated control group 4 days after cohabitation with a SARS-CoV-2 inoculated hamster. However, throat swabs from the intranasal nafamostat-treated hamsters remained SARS-CoV-2 RNA negative for the full 4 days of cohabitation. Significantly lower SARS-CoV-2 RNA concentrations were seen in the nasal turbinates of the nafamostat-treated group compared to the control (p = 0.001). A plaque assay quantified a significantly lower concentration of infectious SARS-CoV-2 in the lungs of the nafamostat-treated group compared to the control (p = 0.035). When taken collectively with the pathological changes observed in the lungs and nasal mucosa, these data are strongly supportive of the utility of intranasally delivered nafamostat for the prevention of SARS-CoV-2 infection.